



ASX ANNOUNCEMENT

Lumos receives US\$5.0 million Milestone Payment from Phase Scientific for FebriDx®

Key Highlights

- Phase Scientific confirms 510(k) with CLIA waiver issued by the FDA satisfies key milestone
- US\$5.0 million milestone payment has now been received by Lumos
- The US\$5.0 million is a pre-payment for future sales that will be recorded as revenue when product is shipped

MELBOURNE, Australia (14 April 2026) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, today received the US\$5.0 million pre-payment for product from US distribution partner, PHASE Scientific (“PHASE”) as per the terms of the PHASE distribution agreement announced 16 July 2025. Receipt of this payment confirms that the US FDA’s 510(k) clearance with CLIA waiver for FebriDx®, as announced on 27 March 2026, satisfies the milestone requirements of the PHASE agreement.

This US\$5.0 million is a pre-payment for future FebriDx® product orders, which will be recognised as sales revenue as purchase orders are received and product is shipped to PHASE. PHASE has now transferred a total of US\$7.5 million in pre-payments to Lumos, with this US\$5.0 million pre-payment being in addition to the US\$2.5 million in pre-payments previously received from PHASE (ASX: 16 July 2025 and 18 August 2025). These prior pre-payments of US\$2.5 million have been applied to orders received to date, including the largest single order of US\$1.3 million announced 1 April 2026.

The granting of CLIA waiver expands the applicability of FebriDx® to a much broader range of settings, including over 300,000 locations across the US, covering a broad range of healthcare settings, spanning primary care physician offices, urgent care clinics, retail health & pharmacy clinics and community health centres that hold a Certificate of Waiver. This milestone marks a significant commercial achievement for Lumos, positioning FebriDx® to reach tens of millions more patients without the need for complex laboratory infrastructure or specialised training. This includes sites such as those run by WellStreet Urgent Care, where FebriDx is being deployed as a front-line test for patients presenting with an acute respiratory infection.

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: *“Receipt of the US\$5.0 million pre-payment confirms that the 510(k) and associated CLIA waiver have satisfied this critical milestone under the PHASE Agreement. We look forward to working closely with PHASE and supporting them as we work together to secure the widespread rollout of FebriDx® across the US market.”*

Lumos would like to emphasize that, whilst pre-payments improve the Company’s near-term cash position and indicate the achievement of key milestones under the PHASE agreement, they are not recognised as revenue until product has been shipped. As such, the Company will continue to update the market of material purchase orders received from PHASE, as these orders allow for pre-payments to be recognised as revenue and, most importantly, are a leading indicator of real-world demand for FebriDx.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598

For personal use only